Improving the adjuvant treatment of HER2-positive breast cancer: APHINITY and ExteNET trials

• REFERENCES

• 1 Moja L, Tagliabue L, Balduzzi S. et al. Trastuzumab containing regimens for early breast cancer [Internet]. The Cochrane Collaboration. editor Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2012. [cited 2017 Jul 19]. Available from http://doi.wiley.com/10.1002/14651858.CD006243.pub2
• 2 Pondé NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 2016; 1 (04) e000073
• 3 Lambertini M, Pondé NF, Solinas C, de Azambuja E. Adjuvant trastuzumab: a 10-year overview of its benefit. Expert Rev Anticancer Ther 2017; 17 (01) 61-74
• 4 Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372 (02) 134-41
• 5 Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro Jr G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C. Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017; 389 10075 1195-205
• 6 Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP. American Society of Clinical Oncology. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breastcancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32 (19) 2078-99
• 7 de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF. et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014; 15 (10) 1137-46
• 8 Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng LM, Liu MC. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13 (01) 25-32
• 9 Gianni L, Pienkowski T, Im Y-H, Im YH, Tseng LM, Liu MC. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17 (06) 791-800
• 10 Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G. et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase iii adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol Off J Am Soc Clin Oncol 2016; 34 (10) 1034-42
• 11 von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377 (02) 122-31
• 12 Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomaševic Z, Denduluri N, Šeparovic R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A. ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18 (12) 1688-1700
• 13 Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G. et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA Oncol 2016; 2 (12) 1557